6088 studies found for:    M2e
Show Display Options
Rank Status Study
1 Completed
Has Results
Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults
Condition: Influenza
Intervention: Biological: VAX102
2 Completed
Has Results
Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults
Condition: Influenza
Interventions: Biological: Influenza A Vaccine: ACAM FLU-A;   Biological: Saline placebo
3 Completed Study to Investigate the Immune Response to Two Doses of VAX102 Healthy Adults
Condition: Influenza
Intervention: Biological: VAX102
4 Completed Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults
Condition: Influenza Infection
Interventions: Biological: VAX102 [Flagellin.HuM2e];   Biological: Placebo
5 Completed Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer
Condition: Breast Cancer
Interventions: Drug: docetaxel;   Drug: doxorubicin
6 Enrolling by invitation Study Of VGX-3400, H5N1 Avian Flu Virus Plasmid DNA With Electroporation Device In Healthy Adult Males
Condition: Healthy
Intervention: Biological: VGX-3400
7 Completed Dose-Finding Study of E7070 in Combination With Irinotecan
Condition: Cancer
Interventions: Drug: E7070 + irinotecan combination;   Drug: Irinotecan + E7070 combination
8 Completed Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue Sarcoma
Condition: Sarcoma
Intervention: Drug: alvocidib
9 Completed ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: ISIS 5132
10 Completed Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: prednisone;   Drug: thalidomide
11 Completed Flavopiridol in Treating Patients With Metastatic Malignant Melanoma
Condition: Melanoma (Skin)
Intervention: Drug: alvocidib
12 Unknown  Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy
Condition: Ovarian Cancer
Interventions: Drug: carboplatin;   Drug: gemcitabine hydrochloride
13 Completed Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer
Condition: Breast Cancer
Interventions: Drug: octreotide acetate;   Drug: tamoxifen citrate
14 Completed Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Condition: Breast Cancer
Interventions: Drug: Raloxifene;   Drug: Tamoxifen
15 Completed Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Drug: marimastat;   Drug: Placebo
16 Completed Safety Study of Anti-Influenza Virus Monoclonal Antibody to Treat Influenza
Condition: Influenza, Human
Interventions: Biological: TCN-032;   Biological: Placebo
17 Completed Pethema Multiple Myeloma 2000
Condition: Multiple Myeloma
Interventions: Drug: Alternating chemotherapy;   Procedure: Autologous Transplantation;   Drug: Maintenance;   Procedure: Second transplantation;   Procedure: ALOGENIC MINI TRASPLANTATION
18 Completed
Has Results
Special Investigation (Follow up Survey of the Study of Adalimumab (D2E7)for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859(NCT00870467)
Condition: Rheumatoid Arthritis
19 Recruiting Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2008
Condition: Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: PEG-L-asparaginase ind;   Drug: PEG-L-asparaginase cons;   Drug: E.coli L-asparaginase;   Drug: High-dose Methotrexate;   Drug: Low-dose Methotrexate;   Drug: Triple intrathecal therapy;   Radiation: Cranial irradiation;   Drug: Daunorubicin
20 Active, not recruiting Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma
Conditions: Wild Type BRAF Stage IV Melanoma;   Unresectable Stage III Melanoma
Intervention: Drug: E7016 plus TMZ

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years